WealthPlan Investment Management LLC Boosts Holdings in Eli Lilly and Company $LLY

WealthPlan Investment Management LLC grew its position in Eli Lilly and Company (NYSE:LLY) by 57.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,325 shares of the company’s stock after buying an additional 1,216 shares during the period. WealthPlan Investment Management LLC’s holdings in Eli Lilly and Company were worth $2,592,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Bridges Investment Management Inc. grew its stake in shares of Eli Lilly and Company by 1.1% in the 2nd quarter. Bridges Investment Management Inc. now owns 11,047 shares of the company’s stock valued at $8,611,000 after buying an additional 123 shares during the period. Callahan Advisors LLC grew its stake in shares of Eli Lilly and Company by 7.9% in the 2nd quarter. Callahan Advisors LLC now owns 17,972 shares of the company’s stock valued at $14,010,000 after buying an additional 1,312 shares during the period. Davidson Investment Advisors purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $220,000. Uptick Partners LLC grew its stake in shares of Eli Lilly and Company by 79.1% in the 2nd quarter. Uptick Partners LLC now owns 514 shares of the company’s stock valued at $401,000 after buying an additional 227 shares during the period. Finally, Dash Acquisitions Inc. grew its stake in shares of Eli Lilly and Company by 2.8% in the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock valued at $387,000 after buying an additional 13 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In other Eli Lilly and Company news, Director J Erik Fyrwald purchased 1,565 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director directly owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This represents a 2.14% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gabrielle Sulzberger purchased 117 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 4,514 shares of company stock worth $2,894,841 over the last three months. 0.13% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on LLY shares. Berenberg Bank reaffirmed a “hold” rating and set a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Morgan Stanley lowered their price objective on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research report on Friday, October 3rd. Daiwa America cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Daiwa Capital Markets cut shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective for the company. in a research report on Sunday, August 17th. Finally, UBS Group lowered their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $948.06.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $826.20 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The stock has a market capitalization of $781.97 billion, a PE ratio of 54.00, a P/E/G ratio of 1.16 and a beta of 0.47. The firm has a 50 day moving average of $745.96 and a two-hundred day moving average of $766.28.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter last year, the company posted $3.92 EPS. The firm’s revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.